New selective CDK12/13 inhibitors and degraders such as YJ9069 demonstrate efficacy in preclinical models of CDK12-deficient prostate cancer, suggesting opportunities for biomarker-guided therapeutic development [18]. This evidence concerns the gene CDK12 and Familial prostate cancer.